Collectively, these findings demonstrate that mutant p53-induced YTHDF2 plays an oncogenic role in glioma development and that elevated YTHDF2 expression is associated with poor clinical outcomes among glioma patients. The gene discussed is YTHDF2; the disease is central nervous system cancer.